L-5-hydroxytryptophan for LSD-induced psychosis
American Journal of Psychiatry April 1, 1983 DOI: 10.1176/ajp.140.4.456 via OpenAlex
Summary
AI-generated from the abstractIn a randomized, double-blind crossover study, the serotonin precursor L-5-hydroxytryptophan reversed the symptoms of a 23-year-old man with LSD-induced psychosis, compared to a placebo. This finding suggests that some LSD-induced psychotic disorders may stem from a relative deficiency of central nervous system serotonin.
Study at a glance
| Characteristics | Randomized controlled trial Double-blind Peer reviewed |
|---|---|
| Sample size | 1 |
| Population | A 23-year-old man suffering from LSD-induced psychosis |
| Interventions | L-5-hydroxytryptophan placebo |
| Topics | LSD Serotonin |
| Keywords | Psychosis 5-hydroxytryptophan Hallucinogen Catatonia |
| Citations | 7 |
| Key finding | L-5-hydroxytryptophan reversed the symptoms of LSD-induced psychosis in a single patient, consistent with the hypothesis that such psychosis may involve a serotonin deficiency. |
Abstract
The serotonin precursor L-5-hydroxytryptophan reversed the symptoms of a 23-year-old man suffering from LSD-induced psychosis who participated in a randomized, double-blind crossover study of the drug and a placebo. This finding is compatible with the speculation that some LSD-induced psychotic disorders may be caused by a relative deficiency of CNS serotonin.